source
- Latigo Biotherapeutics targets non-opioid pain market with $247 M IPOLatigo Biotherapeutics announced details of its planned initial public offering, aiming to raise roughly $247 million to advance its pipeline of non-opioid pain treatments. The company intends to…
- Pfizer expands cost-cutting program, targeting $1 billion in new savings through 2029Pfizer announced it is expanding a cost-cutting initiative first launched in 2023 to further reduce expenses. The new measures are projected to generate about $1 billion in additional savings by 2…